Site Overlay

关于我们

宾派生物是一家致力于放射性诊断和治疗药物创新研发的高科技公司。公司源自世界级的放射性药物科学家领导的强大团队,拥有核医学、脑科学和肿瘤医学等领域数十年尖端医药科技应用成果。公司专注于阿尔兹海默症、帕金森症等神经退行性疾病以及脑肿瘤、前列腺癌等肿瘤疾病的诊疗药物的研发,拥有十数项美国以及国际专利,目前在美国进行4项放射性药物的临床研究。

我们的使命
在抗击脑疾病和癌症的斗争中推动新药创新。
为个性化医疗提供精准的放射性药物,提高患者的生活质量。

我们的愿景
放射性药物创新研究以及临床转化科技全球领先者

研发管线

专有技术

技术支持

为您提供放射性新药(诊断药物、治疗药物)开发全流程解决方案

  • 标记前体技术路线设计与技术支持
  • 药物制备、质量控制与制剂化
  • 新药临床前评价实验的全流程方案设计与技术指导(药物体内外稳定性评价、理化参数评价、体外细胞摄取、模型动物生物分布、摄取机制实验、体外亲和性实验、小动物PET/SPECT显像实验)
  • 新药临床研究的伦理资料申报技术服务
  • 新药申报的全流程资料整理、技术服务与指导

发表文章

宾派致力于放射性诊疗药物的研发以及推广,以下是宾派创始人以及科研团队近期发表的与宾派产品相关的文献资料。

1.阿尔滋海默病(老年痴呆症)
Nuclear Medicine and Biology (2020). “Preclinical evaluation of [18F] D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain.”
https://www.sciencedirect.com/science/article/pii/S0969805120300627
Nuclear Medicine and Biology (2019). “Optimization of solid-phase extraction (SPE) in the preparation of [18F] D3FSP: A new PET imaging agent for mapping Aβ plaques.”
https://www.sciencedirect.com/science/article/pii/S0969805119300502
2.帕金森病
Nuclear Medicine and Biology (2019). “VMAT2 imaging agent, D6-[18F] FP-(+)-DTBZ: Improved radiosynthesis, purification by solid-phase extraction and characterization.”
https://www.sciencedirect.com/science/article/pii/S0969805119300848
Nuclear Medicine and Biology (2018). “Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent.
https://www.sciencedirect.com/science/article/pii/S0969805117302822
3.抑郁症、焦虑症
Nuclear medicine and biology  (2018). “Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain.”

https://www.sciencedirect.com/science/article/pii/S0969805118300544

Nuclear medicine and biology  (2018). “Deuterium‐substituted 2‐(2′‐((dimethylamino) methyl)‐4′‐[18F](fluoropropoxy) phenylthio) benzenamine as a serotonin transporter imaging agent.”

https://onlinelibrary.wiley.com/doi/full/10.1002/jlcr.3626

4.肿瘤
 Journal of Nuclear Medicine (2017). “Metabolic imaging of glutamine in cancer.”
http://jnm.snmjournals.org/content/58/4/533.full
Journal of the American Chemical Society (2011). “Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors.”
https://pubs.acs.org/doi/full/10.1021/ja109203d
5.前列腺癌
Molecular imaging and biology (2019). “[68 Ga] Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68 Ga] Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.”

https://link.springer.com/article/10.1007/s11307-019-01421-7

Nuclear Medicine and Biology (2018). “Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor.”

https://www.sciencedirect.com/science/article/pii/S0969805117302482

新闻

联系我们

中国总部
 
北京市海淀区文慧园北路8号庆亚大厦B座607
联系方式:01056850056
询价邮箱:binpaishengwu@163.com
 
美国研发部
 
Room305,3700 Market Street    
Philadelphia ,USA
Tel:2156623989
Email: zha.zhihao@fiveelevenpharma.com

Copyright © 2020 北京宾派生物技术公司. All Rights Reserved.